Relay Therapeutics discloses three new programs at New Program & Platform event

Relay Therapeutics will provide details on the company’s portfolio during its New Program & Platform event, June 6, 2024. As part of the event, the company will disclose three new programs from its existing pre-clinical pipeline and will review how the Dynamo platform led to these discoveries. The new programs announced today do not change cash guidance, which is expected to fund operations into the second half of 2026. Vascular Malformations: The primary vessel(s) involved determine the sub-type of malformation, which can include venous malformations, cerebral cavernous malformations, lymphatic malformations and PIK3CA-related overgrowth spectrum. A mutant selective PI3Kalpha inhibitor provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability. Relay Therapeutics plans to initiate clinical development of RLY-2608 in vascular malformations in the first quarter of 2025. Fabry Disease: Relay has created the first investigational non-inhibitory chaperone for Fabry disease, which is designed to stabilize the alphaGal protein without inhibiting its activity, thus enabling greater Gb3 clearance across organs. A non-inhibitory chaperone could potentially serve as a chronic treatment option for people with Fabry disease, either as a monotherapy or in combination with enzyme replacement therapy. The company expects its non-inhibitory chaperone to enter the clinic in the second half of 2025. NRAS: existing approved and in-development treatments either target all RAS proteins or target other downstream parts of the pathway such as RAF and MEK, which leads to significant off-target toxicity and limits efficacy. Relay Therapeutics has created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS, while sparing KRAS and HRAS. The company expects to initiate clinical development of its NRAS-selective inhibitor in the second half of 2025.